Avient Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Avient Corporation trades at $35.82 (market cap $3.28B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.78B). The key difference: Avient Corporation is the larger of the two by market cap, and Avient Corporation pays a 3.07% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AVNT | RXRX | |
|---|---|---|
Market Cap | $3.28B | $1.78B |
Sector | Technology | Health |
52-Week High | $43.28 | $6.79 |
52-Week Low | $27.48 | $2.84 |
Enterprise Value | $4.78B | $1.19B |
Dividend Yield | 3.07% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Trailing returns across standard periods
Latest headlines on both assets
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →